CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Elementis Global

Greg Bellotti, Vice President IT/CIO

The Process And Culture Requirements For Exceptional Regulatory Technology

Greg Bellotti

Historically, regulatory projects were passed to IT departments to check the box meeting a compliance or audit standard. For some projects, staff were trained to adopt new process steps with little or no follow-up. Others created audit reports or alerts if activity surpassed limits. Since regulatory projects do not produce revenue, actually they created cost and add time, business buy in was difficult to sell. For small-medium businesses, especially multi-national businesses, overspending in regulatory projects (technology, implementation and continuous operation) could significantly impact operating profit. In six sigma terms, these projects were waste.


But what happens if you are noncompliant? What are the implications? Should we weight cost of non-compliance as a measured risk?


Enter GDPR, the General Data Protection Regulation. GDPR penalties are so material, it instantly garnered focus from CEO’s, Director Boards and investors. This was not a “check the box” regulatory project.


Holistically, Global IT had many tactical efforts to complete; TOMS, DPIA’s, DPO etc. It seemed every vendor was selling a service and toolkit. Timelines were tight and those engaged were frantic with details and checklists. Making matters a bit more challenging was the ambiguity of directives and how to best apply the “reasonable” factor into our plan.


Reviewing risk, project plans, budgets and new regulations in the wings, it became apparent we needed a strategic shift to properly manage GDPR and all compliance projects. We concluded we must treat them as revenue producing projects, projects critical to our sustainability.


Organizationally we learned that technology itself would not solve HR operation or customer management challenges; our success in the aforementioned was a result of intradepartmental understanding, process discovery and strategic goals mapped to a technology solution. That would be the methodology we would apply to regulatory compliance.


No longer small, regional solutions-our regulatory mission adopts best practice methodology we employ for safety, manufacturing, sales and data management. Management committed cultural adoption of platforms, process and people to operate within regulatory compliance rather than report on it as a byproduct of various tools.


Regulatory excellence at all levels:


• Data protection


• Legal protections and requirements


• Financial regulations


• Product registration and sales regulations


• FDA/EMA


No longer a burden of effort but a strategic investment to differentiate Element is as a global leader and steward of exceptional operations enhanced with strategic technology.


Being extraordinary in your regulatory space requires understanding how you must operate at a process level, adopt process operations culturally and crystalize them together with strong technology platforms that meet your current and future needs.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://life-science-testing.lifesciencesreview.com/cioviewpoint/the-process-and-culture-requirements-for-exceptional-regulatory-technology-nwid-298.html